Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation
Journal of the Pediatric Infectious Diseases Society
Acetates; Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections (drug therapy, prevention & control); Hematopoietic Stem Cell Transplantation (adverse effects); Humans; Quinazolines
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
P Daukshus N, Cirincione A, Siver M, et al. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. J Pediatric Infect Dis Soc. 2022;11(7):337-340. doi:10.1093/jpids/piac017